Pfizer's PCSK9 meets Phase-II primary endpoint

Share this article:

Pfizer has issued the results of its Phase-II trial for PCSK9 cholesterol lowering treatment bococizumab (RN316). The drugmaker said the study met its primary endpoint across all doses, “showing that bococizumab significantly reduced lipoprotein cholesterol (LDL-C) from baseline compared to placebo in adults with high cholesterol also taking statin therapy."

Patients were either dosed twice monthly, or once monthly. Both groups “were associated with significant placebo-adjusted reductions in LDL-C” by week 12 of therapy, the drugmaker stated.

Pfizer's global medicines development lead, Dr. Steven Romano, said “we are pleased with the outcome of this Phase 2b study and continue to maintain focus on developing our Phase-III program, which includes two CV outcome studies in populations at high risk from cardiovascular events. Recent guidelines emphasize the reduction of CV risk as the primary goal of lipid therapy" for those patients, he added. The drug's Phase-III trial began in October 2013.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.

IRS struggles with device tax

A Treasury report says the IRS is having trouble identifying who owes it money.

White House proposes Hobby Lobby alternative

A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.